Alpha-synuclein gene structure, evolution, and protein aggregation

Neural Regeneration Research

Volumn 5, Issue 18, 2010, Pages 1423-1428

  Xiong, Lili ^a   Zhao, Peng ^a   Guo, Zhiyun ^a   Zhang, Jianhua ^b   Li, Diqiang ^c   Mao, Canquan ^a  

^a SOUTHWEST JIAOTONG UNIVERSITY   (China)

^b University of Alabama at Birmingham   (United States)

^c RESEARCH INSTITUTE OF FORESTRY   (China)

Author keywords

Aggregation in vitro; Bioinformatics analysis; Neural regeneration; Neurodegenerative diseases; Parkinson's disease; Review; synuclein

Indexed keywords

ALPHA SYNUCLEIN; AMINO ACID; AMYLOID BETA PROTEIN; BETA SYNUCLEIN; GAMMA SYNUCLEIN;

ALPHA SYNUCLEIN GENE; AMINO ACID SEQUENCE; AMINO TERMINAL SEQUENCE; ARTICLE; BETA SYNUCLEIN GENE; CARBOXY TERMINAL SEQUENCE; EXON; GAMMA SYNUCLEIN GENE; GENE; GENE FUNCTION; GENE SEQUENCE; GENE STRUCTURE; GENE TARGETING; GENETIC CODE; GENETIC DISTANCE; HUMAN; MOLECULAR EVOLUTION; NONHUMAN; NUCLEOTIDE SEQUENCE; PARKINSON DISEASE; PHYLOGENETIC TREE; PROTEIN AGGREGATION; PROTEIN STRUCTURE; RNA SPLICING;

EID: 79960382934     PISSN: 16735374     EISSN: None     Source Type: Journal    
DOI: 10.3969/j.issn.1673-5374.2010.18.011     Document Type: Article

References (38)

1. Maroteaux L, Campanelli JT, Scheller RH. Synuclein: a neuron-specific protein localized to the nucleus and presynaptic nerve terminal. J Neurosci. 1988;8(8):2804-2815.
2. Touchman JW, Dehejia A, Chiba-Falek O, et al. Human and mouse alpha-synuclein genes: comparative genomic sequence analysis and identification of a novel gene regulatory element. Genome Res. 2001;11(1):78-86.
3. Hong L, Ko HW, Gwag BJ, et al. The cDNA cloning and ontogeny of mouse alpha-synuclein. Neuroreport. 1998;9(6):1239-1243.
4. Yuan Z, Zhao X, Yan F, et al. Beta-synuclein protein from Xenopus laevis: overexpression in Escherichia coli of the GST-tagged protein and production of polyclonal antibodies. Biochemistry (Mosc). 2007;72(11):1270-1278.
5. Lavedan C. The synuclein family. Genome Res. 1998;8(9): 871-880.
6. George JM. The synucleins. Genome Biol. 2002;3(1): REVIEWS3002.
7. Marxreiter F, Nuber S, Kandasamy M, et al. Changes in adult olfactory bulb neurogenesis in mice expressing the A30P mutant form of alpha-synuclein. Eur J Neurosci. 2009;29(5):879-890.
8. Linnertz C, Saucier L, Ge D, et al. Genetic regulation of alpha-synuclein mRNA expression in various human brain tissues. PLoS One. 2009;4(10):e7480.
9. Ben Gedalya T, Loeb V, Israeli E, et al. Alpha-synuclein and polyunsaturated fatty acids promote clathrin-mediated endocytosis and synaptic vesicle recycling. Traffic. 2009;10(2): 218-234.
10. Morris AM, Finke RG. Alpha-synuclein aggregation variable temperature and variable pH kinetic data: a re-analysis using the Finke-Watzky 2-step model of nucleation and autocatalytic growth. Biophys Chem. 2009;140(1-3):9-15.
11. Koo HJ, Choi MY, Im H. Aggregation-defective alpha-synuclein mutants inhibit the fibrillation of Parkinson's disease-linked alpha-synuclein variants. Biochem Biophys Res Commun. 2009; 386(1):165-169.
12. Hirohata M, Ono K, Morinaga A, et al. Anti-aggregation and fibril-destabilizing effects of sex hormones on alpha-synuclein fibrils in vitro. Exp Neurol. 2009;217(2):434-439.
13. Chen X, de Silva HA, Pettenati MJ, et al. The human NACP/alpha-synuclein gene: chromosome assignment to 4q21.3-q22 and TaqI RFLP analysis. Genomics. 1995;26(2): 425-427.
14. Spillantini MG, Divane A, Goedert M. Assignment of human alpha-synuclein (SNCA) and beta-synuclein (SNCB) genes to chromosomes 4q21 and 5q35. Genomics. 1995;27(2):379-381.
15. Ninkina NN, Alimova-Kost MV, Paterson JW, et al. Organization, expression and polymorphism of the human persyn gene. Hum Mol Genet. 1998;7(9):1417-1424.
16. Beyer K. Alpha-synuclein structure, posttranslational modification and alternative splicing as aggregation enhancers. Acta Neuropathol. 2006;112(3):237-251.
17. Beyer K, Domingo-Sàbat M, Humbert J, et al. Differential expression of alpha-synuclein, parkin, and synphilin-1 isoforms in Lewy body disease. Neurogenetics. 2008;9(3):163-172.
18. Beyer K, Domingo-Sábat M, Lao JI, et al. Identification and characterization of a new alpha-synuclein isoform and its role in Lewy body diseases. Neurogenetics. 2008;9(1):15-23.
19. Beyer K, Humbert J, Ferrer A, et al. Low alpha-synuclein 126 mRNA levels in dementia with Lewy bodies and Alzheimer disease. Neuroreport. 2006;17(12):1327-1330.
20. Mihajlovic M, Lazaridis T. Membrane-bound structure and energetics of alpha-synuclein. Proteins. 2008;70(3):761-778.
21. Kim YS, Laurine E, Woods W, et al. A novel mechanism of interaction between alpha-synuclein and biological membranes. J Mol Biol. 2006;360(2):386-397.
22. Wu B, Liu Q, Duan C, et al. Phosphorylation of alpha-synuclein upregulates tyrosine hydroxylase activity in MN9D cells. Acta Histochem. 2009.
23. Okochi M, Walter J, Koyama A, et al. Constitutive phosphorylation of the Parkinson's disease associated alpha-synuclein. J Biol Chem. 2000;275(1):390-397.
24. Bosco DA, Fowler DM, Zhang Q, et al. Elevated levels of oxidized cholesterol metabolites in Lewy body disease brains accelerate alpha-synuclein fibrillization. Nat Chem Biol. 2006;2(5):249-253.
25. Conway KA, Lee SJ, Rochet JC, et al. Acceleration of oligomerization, not fibrillization, is a shared property of both alpha-synuclein mutations linked to early-onset Parkinson's disease: implications for pathogenesis and therapy. Proc Natl Acad Sci U S A. 2000;97(2):571-576.
26. Mukaetova-Ladinska EB, Hurt J, Jakes R, et al. Alpha-synuclein inclusions in Alzheimer and Lewy body diseases. J Neuropathol Exp Neurol. 2000;59(5):408-417.
27. Conway KA, Harper JD, Lansbury PT. Accelerated in vitro fibril formation by a mutant alpha-synuclein linked to early-onset Parkinson disease. Nat Med. 1998;4(11):1318-1320.
28. Li J, Uversky VN, Fink AL. Effect of familial Parkinson's disease point mutations A30P and A53T on the structural properties, aggregation, and fibrillation of human alpha-synuclein. Biochemistry. 2001;40(38):11604-11613.
29. Waxman EA, Duda JE, Giasson BI. Characterization of antibodies that selectively detect alpha-synuclein in pathological inclusions. Acta Neuropathol. 2008;116(1):37-46.
30. Bellucci A, Collo G, Sarnico I, et al. Alpha-synuclein aggregation and cell death triggered by energy deprivation and dopamine overload are counteracted by D2/D3 receptor activation. J Neurochem. 2008;106(2):560-577.
31. Burke WJ, Kumar VB, Pandey N, et al. Aggregation of alpha-synuclein by DOPAL, the monoamine oxidase metabolite of dopamine. Acta Neuropathol. 2008;115(2):193-203.
32. Moussa CE, Mahmoodian F, Tomita Y, et al. Dopamine differentially induces aggregation of A53T mutant and wild type alpha-synuclein: insights into the protein chemistry of Parkinson's disease. Biochem Biophys Res Commun. 2008;365(4):833-839.
33. Leong SL, Cappai R, Barnham KJ, et al. Modulation of alpha-synuclein aggregation by dopamine: a review. Neurochem Res. 2009;34(10):1838-1846.
34. Li HT, Lin DH, Luo XY, et al. Inhibition of alpha-synuclein fibrillization by dopamine analogs via reaction with the amino groups of alpha-synuclein. Implication for dopaminergic neurodegeneration. FEBS J. 2005;272(14):3661-3672.
35. Emadi S, Barkhordarian H, Wang MS, et al. Isolation of a human single chain antibody fragment against oligomeric alpha-synuclein that inhibits aggregation and prevents alpha-synuclein-induced toxicity. J Mol Biol. 2007;368(4):1132-1144.
36. Zhou C, Emadi S, Sierks MR, et al. A human single-chain Fv intrabody blocks aberrant cellular effects of overexpressed alpha-synuclein. Mol Ther. 2004;10(6):1023-1031.
37. Pandey N, Strider J, Nolan WC, et al. Curcumin inhibits aggregation of alpha-synuclein. Acta Neuropathol. 2008;115(4): 479-489.
38. Bodles AM, El-Agnaf OM, Greer B, et al. Inhibition of fibril formation and toxicity of a fragment of alpha-synuclein by an N-methylated peptide analogue. Neurosci Lett. 2004;359(1-2): 89-93.